The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 06, 2018
Filed:
Apr. 20, 2016
Cellcentric Ltd, Cambridge, Cambridgeshire, GB;
Neil Anthony Pegg, Cambridge, GB;
David Michel Adrien Taddei, Nottingham, GB;
Stuart Thomas Onions, Nottingham, GB;
Eric Sing Yuen Tse, Nottingham, GB;
Richard James Brown, Nottingham, GB;
David Kenneth Mycock, Nottingham, GB;
David Cousin, Nottingham, GB;
Anil Patel, Nottingham, GB;
CELLCENTRIC LTD, Cambridge, Cambrigeshire, GB;
Abstract
A compound which is a benzimidazolyl isoxazole of formula (I): wherein: Rand R, which are the same or different, are each H or Calkyl; R, Rand R, which are the same or different, are each H or F; X is -(alk-, -alk-C(═O)—NR—, -alk-NR—C(═O)— or -alk-C(═O)—; Ris selected from —S(═O)R'; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: Rand R, which are the same or different, are each H or Calkyl, or Rand Rform, together with the C atom to which they are attached, a Ccycloalkyl group; Rand R, which are the same or different, are each H, Calkyl, OH or F; Ris phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is Calkylene; R′ is Calkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.